HALO · Halozyme Therapeutics, Inc.

Summary

Halozyme Therapeutics, Inc. filed an 8-K on March 12, 2026, with Item 5.02 regarding departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements, as indicated by the external item hint. Exhibit 99.1 is a press release dated March 12, 2026.

Key takeaways

• Item 5.02 disclosure on executive or director changes
• Exhibit 99.1: Press Release dated 2026-03-12
• Filing date: 2026-03-12
• Form Type: 8-K